Clinical trial / 2001
Oral curcuma extract was well tolerated but showed low bioavailability in colorectal cancer
Fifteen patients with advanced colorectal cancer received 440 to 2,200 mg daily of Curcuma extract for up to 4 months. Neither curcumin nor metabolites were detectable in blood or urine, though curcumin was found in feces. A dose of 440 mg reduced lymphocytic glutathione S-transferase by 59% at day 29, but higher doses did not, and five patients had radiologically stable disease for 2-4 months.
- Study type
- Dose-escalation pilot clinical trial
- Who was studied
- 15 patients with advanced colorectal cancer
- What was measured
- Safety, pharmacokinetics, and blood cell biomarkers
THE PAPER
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. Clin Cancer Res, 2001.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.